<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Atrial fibrillation in adults: Selection of candidates for anticoagulation
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Atrial fibrillation in adults: Selection of candidates for anticoagulation
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Atrial fibrillation in adults: Selection of candidates for anticoagulation
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Warren J Manning, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Daniel E Singer, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Gregory YH Lip, MD, FRCPE, FESC, FACC
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Peter J Zimetbaum, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Scott E Kasner, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Bradley P Knight, MD, FACC
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Susan B Yeon, MD, JD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 11, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H2495222914">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Atrial fibrillation (AF) is a major cause of morbidity and mortality in adults. While ischemic stroke due to embolization of left atrial thrombi is the most frequent clinical manifestation of embolization, embolization to other locations in the systemic circulation (and in the pulmonary circulation from right atrial thrombi) also occurs but is less commonly recognized. Stroke associated with AF tends to be more extensive/larger than stroke related to carotid artery disease. Chronic oral anticoagulation (OAC) is recommended to reduce the risk of thromboembolism for most patients with AF. However, such therapy is associated with an increased risk of bleeding, and recommendations for its use must take both benefit and risk into account through shared decision-making with the patient. (See
         <a class="medical medical_review" href="/z/d/html/1059.html" rel="external">
          "Stroke in patients with atrial fibrillation"
         </a>
         .)
        </p>
        <p>
         This topic will focus on identifying which patients with AF require long-term/chronic OAC with either vitamin K antagonist (VKA; eg,
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         ) or direct oral anticoagulants (DOAC; also referred to as non-vitamin K oral anticoagulants [NOAC]). The discussion here excludes patients with rheumatic mitral stenosis that is severe or clinically significant (mitral valve area ≤1.5 cm
         <sup>
          2
         </sup>
         ), a bioprosthetic valve (surgical or bioprosthetic) within the first three to six months after implantation, or a mechanical heart valve. Management for patients with these valve conditions is briefly discussed in a section below that provides links to related topics. (See
         <a class="local">
          'Patients with valvular heart disease'
         </a>
         below.)
        </p>
        <p>
         Other potentially relevant topics to the reader include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Choice of OAC for AF (see
         <a class="medical medical_review" href="/z/d/html/1031.html" rel="external">
          "Atrial fibrillation in adults: Use of oral anticoagulants"
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/906.html" rel="external">
          "Prevention of embolization prior to and after restoration of sinus rhythm in atrial fibrillation"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1059.html" rel="external">
          "Stroke in patients with atrial fibrillation"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/928.html" rel="external">
          "Atrial fibrillation: Left atrial appendage occlusion"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph utd-adt-cnt utd-adt-pathwys">
          ●
         </span>
         <span class="utd-adt-cnt utd-adt-pathwys utd-content-120056">
          (Related Pathway(s):
          <a class="utd-content-120056" href="/pathway/120056?topicRef=128998&amp;source=see_link">
           Atrial fibrillation: Anticoagulation for adults with atrial fibrillation
          </a>
          .)
         </span>
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2603136657">
         <span class="h1">
          APPROACH TO DECIDING WHETHER TO ANTICOAGULATE
         </span>
        </p>
        <p class="headingAnchor" id="H1601062998">
         <span class="h2">
          Decision-making based upon risk assessment
         </span>
         <span class="headingEndMark">
          —
         </span>
         A first step in deciding which patients with AF should receive long-term oral anticoagulation (OAC) is to assess the individual patient’s risks of thromboembolism and bleeding along with patient preferences. Long-term anticoagulation lowers the risk of clinical embolization in patients with AF, but its use is associated with an increased risk of bleeding.
        </p>
        <p>
         The benefits and risks of OAC with respect to reduction in risk of stroke and increment in risk of bleeding must be carefully considered and discussed with each patient. The greater the estimated reduction in absolute stroke risk compared with the increase in absolute risk of life-threatening or severely debilitating bleeding (such as intracranial hemorrhage), the more likely a patient is to benefit from long-term OAC. The benefit generally outweighs the risk for all but those with the lowest risk of thromboembolism. In cases of more balanced stroke reduction and bleeding risks, OAC is less likely to provide a net benefit. Risk scores are commonly used to assess thromboembolic and bleeding risks, although these tools are subject to a number of limitations. (See
         <a class="local">
          'CHA2DS2-VASc score'
         </a>
         below and
         <a class="local">
          'Bleeding risk'
         </a>
         below.)
         <span class="utd-adt-cnt utd-adt-pathwys utd-content-120056">
          (Related Pathway(s):
          <a class="utd-content-120056" href="/pathway/120056?topicRef=128998&amp;source=see_link">
           Atrial fibrillation: Anticoagulation for adults with atrial fibrillation
          </a>
          .)
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Our approach to deciding whether to prescribe anticoagulant therapy for patients with AF (without severe or clinically significant rheumatic mitral stenosis [mitral valve area ≤1.5 cm
         <sup>
          2
         </sup>
         ], a bioprosthetic valve [surgical or bioprosthetic] within the first three to six months after implantation, or a mechanical valve) is as follows:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For a CHA
         <sub>
          2
         </sub>
         DS
         <sub>
          2
         </sub>
         -VASc score ≥2 in males or ≥3 in females (
         <a class="calc calc_professional" href="/z/d/html/99815.html" rel="external">
          calculator 1
         </a>
         )  (
         <a class="graphic graphic_table graphicRef94752" href="/z/d/graphic/94752.html" rel="external">
          table 1
         </a>
         ), we recommend chronic OAC.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For a CHA
         <sub>
          2
         </sub>
         DS
         <sub>
          2
         </sub>
         -VASc score of 1 in males and 2 in females (
         <a class="calc calc_professional" href="/z/d/html/99815.html" rel="external">
          calculator 1
         </a>
         )  (
         <a class="graphic graphic_table graphicRef94752" href="/z/d/graphic/94752.html" rel="external">
          table 1
         </a>
         ), the specific nonsex risk factor present and the documented burden of AF influences decision making:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For patients with CHA
         <sub>
          2
         </sub>
         DS
         <sub>
          2
         </sub>
         -VASc score of 1 in males and 2 in females based on age 65 to 74 years, we recommend chronic OAC. Age 65 to 74 years is a stronger risk factor than the other factors conferring one CHA
         <sub>
          2
         </sub>
         DS
         <sub>
          2
         </sub>
         -VASc score point [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For patients with other risk factors, the decision to anticoagulate is based upon the specific nonsex risk factor and the burden of AF. For patients with very low burden of AF (eg, AF that is well documented as limited to an isolated episode that may have been due to a reversible cause such as recent surgery, heavy alcohol ingestion, or sleep deprivation), it may be reasonable to forgo chronic OAC and institute close surveillance for recurrent AF, although it may not be possible to reliably estimate AF burden from surveying symptoms or infrequent monitoring. The frequency and duration of AF episodes vary widely over time and episodes are often asymptomatic. (See
         <a class="medical medical_review" href="/z/d/html/113847.html" rel="external">
          "Atrial fibrillation in patients undergoing noncardiac surgery", section on 'Anticoagulation after surgery'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1011.html" rel="external">
          "Atrial fibrillation and flutter after cardiac surgery", section on 'Anticoagulation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with a CHA
         <sub>
          2
         </sub>
         DS
         <sub>
          2
         </sub>
         -VASc of 0 in males or 1 in females (
         <a class="calc calc_professional" href="/z/d/html/99815.html" rel="external">
          calculator 1
         </a>
         ) (
         <a class="graphic graphic_table graphicRef94752" href="/z/d/graphic/94752.html" rel="external">
          table 1
         </a>
         ), we suggest
         <strong>
          against
         </strong>
         anticoagulant therapy. Patient values and preferences may impact the decision. For example, a patient who is particularly stroke averse and is not at increased risk for bleeding (see
         <a class="local">
          'Bleeding risk'
         </a>
         below) may reasonably choose anticoagulation, particularly if the patient is a candidate for treatment with a direct oral anticoagulant (DOAC).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For all potential candidates for OAC, bleeding risk and related possible contraindications to OAC should be reviewed  (
         <a class="graphic graphic_table graphicRef107527" href="/z/d/graphic/107527.html" rel="external">
          table 2
         </a>
         and
         <a class="graphic graphic_table graphicRef75259" href="/z/d/graphic/75259.html" rel="external">
          table 3
         </a>
         ). The appropriate use of bleeding risk assessment is to draw attention to modifiable bleeding risk factors that can be mitigated, and to flag patients with high bleeding risk for early review and follow-up and to identify potential candidates for left atrial appendage occlusion [
         <a href="#rid2">
          2-6
         </a>
         ]. (See
         <a class="local">
          'Bleeding risk'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/1324.html" rel="external">
          "Management of warfarin-associated bleeding or supratherapeutic INR", section on 'Mitigating bleeding risk'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/119889.html" rel="external">
          "Risks and prevention of bleeding with oral anticoagulants", section on 'Risk factors for bleeding'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3507160573">
         <span class="h2">
          Effects of anticoagulation
         </span>
         <span class="headingEndMark">
          —
         </span>
         In identifying which patients with AF are likely to benefit from OAC, the relative risk reduction in thromboembolism with OAC identified in randomized trials (see
         <a class="local">
          'General efficacy'
         </a>
         below) is combined with estimates of baseline risk using the CHA
         <sub>
          2
         </sub>
         DS
         <sub>
          2
         </sub>
         -VASc score to estimate the expected absolute risk reduction from OAC (see
         <a class="local">
          'CHA2DS2-VASc score'
         </a>
         below). The estimated absolute risk reduction for thromboembolic events is weighed against the estimated increase in absolute risk of intracranial hemorrhage (ICH) and other major bleeding complications. (See
         <a class="local">
          'Bleeding risk'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1875654363">
         <span class="h3">
          General efficacy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with AF, randomized trials have shown that therapeutic OAC (vitamin K antagonist [VKA] or DOAC) reduces the risk of ischemic stroke and other embolic events by approximately two-thirds compared with placebo irrespective of baseline risk  (
         <a class="graphic graphic_figure graphicRef79839" href="/z/d/graphic/79839.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid7">
          7-17
         </a>
         ].
        </p>
        <p>
         A meta-analysis included six randomized trials comparing VKA (
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         ) with placebo or no treatment in a total of 2900 participants with AF (mean age at entry 69 years, 20 percent with prior stroke or transient ischemic attack [TIA]) [
         <a href="#rid14">
          14
         </a>
         ]. The overall rate of stroke was 2.2 percent/patient year in the warfarin group and 6.0 percent/patient year in the control group (relative risk reduction 0.64; 95% CI 0.49-0.74). The absolute risk reduction was 2.7 percent/year for primary prevention and 8.4 percent/year for secondary prevention. With warfarin therapy, all-cause mortality was reduced by 1.6 percent/year (relative risk reduction 0.26; 95% CI 0.03-0.43).
        </p>
        <p>
         While most of the evidence comparing OAC with placebo in patients involved treatment with VKA, a trial comparing
         <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">
          edoxaban
         </a>
         15 mg daily with placebo in patients with AF ≥80 years old with low body weight found a similar relative reduction in risk of stroke or systemic embolism (2.3 versus 6.7 percent/year; hazard ratio 0.34, 95% CI 0.19-0.61) [
         <a href="#rid18">
          18
         </a>
         ]. The possible implications of this study for edoxaban dose are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1031.html" rel="external">
          "Atrial fibrillation in adults: Use of oral anticoagulants"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1031.html" rel="external">
          "Atrial fibrillation in adults: Use of oral anticoagulants", section on 'DOACs'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1185097653">
         <span class="h3">
          CHA2DS2-VASc score
         </span>
        </p>
        <p class="headingAnchor" id="H689580337">
         <span class="h4">
          Use
         </span>
         <span class="headingEndMark">
          —
         </span>
         We use the CHA
         <sub>
          2
         </sub>
         DS
         <sub>
          2
         </sub>
         -VASc score (
         <a class="calc calc_professional" href="/z/d/html/99815.html" rel="external">
          calculator 1
         </a>
         ) to estimate thromboembolic risk in patients with AF, while recognizing its limitations (see
         <a class="local">
          'Potential alternatives'
         </a>
         below and
         <a class="local">
          'Limitations'
         </a>
         below). This estimation of baseline thromboembolic risk is combined with the above information on relative risk reduction (see
         <a class="local">
          'General efficacy'
         </a>
         above) to estimate the expected absolute risk reduction.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The annual risk of ischemic stroke in untreated patients is estimated to be 0.2, 0.6, and 2.2 percent for those with CHA
         <sub>
          2
         </sub>
         DS
         <sub>
          2
         </sub>
         -VASc scores of 0, 1, and 2  (
         <a class="graphic graphic_table graphicRef94752" href="/z/d/graphic/94752.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid19">
          19
         </a>
         ]. However, stroke rates have varied substantially among studies, which may be due to differences in study populations and methodologies [
         <a href="#rid2">
          2,20-24
         </a>
         ]. As an example, studies examining ischemic stroke rates in patients with a single risk factor have identified risks of &lt;1 to 2.7 percent/year [
         <a href="#rid25">
          25-27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Among patients with AF, ischemic stroke is the dominant type of thromboembolic event. As an example, in a study including data on 39,973 participants in four randomized trials of anticoagulation, the incidence of nonstroke systemic embolic events (SEEs) was 0.23/100 person-years, and the incidence of cerebral embolism was 1.92/100 person-years [
         <a href="#rid28">
          28
         </a>
         ]. Among those with SEEs, 58 percent occurred in the lower extremities, 31 percent in the visceral-mesenteric system, and 11 percent in the upper extremities.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among patients with AF treated with OAC, annual stroke risk is lowered by approximately two-thirds to &lt;0.1, 0.2, and 0.6 percent, respectively. In addition to the lowering of stroke risk, there is evidence that
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         , compared with no anticoagulant therapy, leads to less severe stroke episodes and lower 30-day stroke mortality [
         <a href="#rid14">
          14,29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The annual risk of intracranial bleeding with
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         is 0.2, 0.3, and 0.5 percent, respectively. The risk of ICH with DOAC is approximately half of that with VKA  (
         <a class="graphic graphic_table graphicRef131871" href="/z/d/graphic/131871.html" rel="external">
          table 4
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/1031.html" rel="external">
          "Atrial fibrillation in adults: Use of oral anticoagulants", section on 'Choice of anticoagulant'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Among adults with AF, females have a modestly higher risk of thromboembolism than males, but female sex is associated with increased risk primarily in patients with at least two CHA
         <sub>
          2
         </sub>
         DS
         <sub>
          2
         </sub>
         -VASc score non-sex risk score points [
         <a href="#rid1">
          1,30
         </a>
         ]. Thus, we focus on non-sex risk factors when deciding whether OAC is indicated.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          For CHA
         </strong>
         <strong>
          <sub>
           2
          </sub>
         </strong>
         <strong>
          DS
         </strong>
         <strong>
          <sub>
           2
          </sub>
         </strong>
         <strong>
          -VASc score ≥2 in males or ≥3 in females
         </strong>
         (when the risk score points are from two or more non-sex risk factors), the benefit from OAC generally exceeds the risks of severe bleeding [
         <a href="#rid19">
          19,31-33
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          For CHA
         </strong>
         <strong>
          <sub>
           2
          </sub>
         </strong>
         <strong>
          DS
         </strong>
         <strong>
          <sub>
           2
          </sub>
         </strong>
         <strong>
          -VASc score of 1 in males or 2 in females
         </strong>
         (one non-sex risk factor with a value of 1), the risk of thromboembolism varies depending upon the non-sex risk factor [
         <a href="#rid1">
          1
         </a>
         ]. Among the risk factors with a one-point value, age 65 to 74 years and the presence of heart failure have the greatest effect on thromboembolic risk [
         <a href="#rid1">
          1
         </a>
         ], and OAC is recommended in patients with any of these risk factors.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          For CHA
         </strong>
         <strong>
          <sub>
           2
          </sub>
         </strong>
         <strong>
          DS
         </strong>
         <strong>
          <sub>
           2
          </sub>
         </strong>
         <strong>
          - VASc score of 0 in males or 1 in females
         </strong>
         (zero nonsex risk factors), the thromboembolic risk is low [
         <a href="#rid27">
          27
         </a>
         ], so no OAC is suggested. (See
         <a class="local">
          'Approach to deciding whether to anticoagulate'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p>
         The
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         versus placebo or
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         trials were reported in the early 1990s, raising concerns that the findings may not be applicable to contemporary clinical practice [
         <a href="#rid31">
          31,34,35
         </a>
         ]. Studies evaluating more contemporary data have found that the absolute risk of stroke in untreated patients has fallen from approximately 8 percent/year to 4 or 5 percent/year  (
         <a class="graphic graphic_table graphicRef94752" href="/z/d/graphic/94752.html" rel="external">
          table 1
         </a>
         ), but the relative risk reduction attributable to anticoagulant therapy is in the same range as earlier studies [
         <a href="#rid36">
          36,37
         </a>
         ]. A two-thirds risk reduction in thromboembolism using the more contemporary lower absolute risks is clinically important for patients with two or more nonsex risk factors and for selected patients with one nonsex risk factor.
        </p>
        <p>
         Comparisons of the effects of VKA and DOAC are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/1031.html" rel="external">
          "Atrial fibrillation in adults: Use of oral anticoagulants"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H320314639">
         <span class="h4">
          Potential alternatives
         </span>
         <span class="headingEndMark">
          —
         </span>
         A variety of risk scores, imaging methods, and biomarkers have been studied for their potential predictive value for thromboembolic risk in patients with AF [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
         The CHA
         <sub>
          2
         </sub>
         DS
         <sub>
          2
         </sub>
         -VASc score has been compared with potential alternatives including the CHADS
         <sub>
          2
         </sub>
         and ATRIA risk scores  (
         <a class="graphic graphic_table graphicRef94752" href="/z/d/graphic/94752.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_table graphicRef90032" href="/z/d/graphic/90032.html" rel="external">
          table 5
         </a>
         ). The clinical utility of a risk score for individuals with AF hinges primarily on its accuracy in identifying those at lowest risk for thromboembolism, as anticoagulation is generally recommended for individuals with all but the lowest level of risk. Systematic reviews suggest that the CHA
         <sub>
          2
         </sub>
         DS
         <sub>
          2
         </sub>
         -VASc score generally performs better than the CHADS
         <sub>
          2
         </sub>
         and ATRIA scores in identifying low-risk patients, although there have been some discrepant results for comparisons of CHA
         <sub>
          2
         </sub>
         DS
         <sub>
          2
         </sub>
         -VASc and ATRIA [
         <a href="#rid38">
          38
         </a>
         ]. However, all these risk scores are subject to the limitations discussed below. (See
         <a class="local">
          'Limitations'
         </a>
         below.)
        </p>
        <p>
         A potential alternative to the risk score approach is to calculate the risk for each patient based upon risk factors including age as a continuous variable using the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fhjerteforeningen.shinyapps.io%2Friskvisrr%2F&amp;token=rlSOpsTt2XHldO%2Bge%2FihD1gejfdiX1D06ntePWQy7mea6i%2F4AfuMxUJ3aTRzY7CG7YvyPwUzwoR%2BZ6bQJ6l5qA%3D%3D&amp;TOPIC_ID=128998" target="_blank">
          Calculator of Absolute Stroke Risk (CARS)
         </a>
         [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         For patients with AF, there is no established role for routine cardiac imaging to assess thromboembolic risk. Transesophageal echocardiography (TEE) is used in patients with AF primarily to evaluate left and right atrial appendage anatomy/function to identify individuals who are free of atrial thrombi and are therefore candidates for early cardioversion (see
         <a class="medical medical_review" href="/z/d/html/906.html" rel="external">
          "Prevention of embolization prior to and after restoration of sinus rhythm in atrial fibrillation"
         </a>
         ). Thromboembolic risk is associated with cardiac imaging findings, including evidence of left atrial thrombus (generally assessed by TEE; less commonly assessed by cardiovascular magnetic resonance [CMR] or cardiac computed tomography [CCT]) and depressed left ventricular ejection fraction (which can be assessed by transthoracic echocardiography, TEE, CMR, CCT, or nuclear methods) [
         <a href="#rid39">
          39
         </a>
         ]. However, imaging findings have not been shown to improve risk stratification in patients with AF [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3863991115">
         <span class="h4">
          Limitations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Risk scores to estimate thromboembolic risk in patients with AF have limited predictive value when applied to individual patients.
        </p>
        <p>
         One limitation is that risk scores utilize point systems that do not reflect differences in risk among included risk factors. Risk factors assigned equal point values are associated with substantially different risks, as illustrated by the following examples for the CHA
         <sub>
          2
         </sub>
         DS
         <sub>
          2
         </sub>
         -VASc score  (
         <a class="graphic graphic_table graphicRef94752" href="/z/d/graphic/94752.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Age 65 to 74 years is associated with substantially greater stroke risk than other risk factors assigned one point.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A history of prior stroke, TIA, or thromboembolic event is assigned two points, but the risk associated with this risk factor is more than five times the risk associated with risk factors assigned one point.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The continuous risk of age is lumped into categories, so that ages 65 years and 74 years each confer one point, despite the much higher actual risk associated with the older age.
        </p>
        <p>
        </p>
        <p>
         Another limitation is that the event rates observed in populations used to generate risk score may differ from those occurring in different clinical settings (eg, community versus hospitalized) and patient populations with differing risk profiles.
        </p>
        <p>
         Also, some clinical features or conditions may impact the risk of thromboembolism but are not included in risk models; these include the duration or frequency of episodes of paroxysmal AF and the presence of conditions such as chronic kidney disease and elevated troponin level. Prediabetes has also been implicated as a possible risk factor for stroke in patients with AF [
         <a href="#rid40">
          40
         </a>
         ]. The potential role of troponin measurement in the assessment of the risk of embolization in patients with AF is discussed separately. (See
         <a class="local">
          'Chronic kidney disease'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/1469.html" rel="external">
          "Elevated cardiac troponin concentration in the absence of an acute coronary syndrome", section on 'Atrial fibrillation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2925988103">
         <span class="h3">
          Bleeding risk
         </span>
         <span class="headingEndMark">
          —
         </span>
         When OAC is considered, the major safety concern is the increased risk of bleeding, especially major bleeding, which includes events that require hospitalization, transfusion, or surgery, or that involve particularly sensitive anatomic locations. Thus, bleeding risk and related contraindications to OAC should be reviewed  (
         <a class="graphic graphic_table graphicRef107527" href="/z/d/graphic/107527.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
         A systematic review comparing various bleeding risk scores in patients with AF found that the HAS-BLED risk score  (
         <a class="graphic graphic_table graphicRef75259" href="/z/d/graphic/75259.html" rel="external">
          table 3
         </a>
         ) was the best predictor of bleeding risk [
         <a href="#rid2">
          2
         </a>
         ], although all bleeding risk scores provide imprecise estimates for individual patients, do not provide estimates for specific types of major bleeds, and are based upon bleeding risk with
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         . Two more recent studies confirmed the efficacy of the HAS-BLED score was comparable to or better than ORBIT score in patients treated with DOACs [
         <a href="#rid41">
          41,42
         </a>
         ]. Among patients with AF, the three most important predictors of major bleeding (including ICH) are overanticoagulation with warfarin (defined as an international normalized ratio greater than 3.0), prior stroke, and older patient age [
         <a href="#rid31">
          31,43-45
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/119889.html" rel="external">
          "Risks and prevention of bleeding with oral anticoagulants"
         </a>
         .)
        </p>
        <p>
         The risk of bleeding was evaluated in a cohort of over 16,000 patients diagnosed with AF between 2005 and 2010 [
         <a href="#rid37">
          37
         </a>
         ]. The incidence of major bleeding with current, recent, past, or no VKA (
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         ) exposure was 3.8, 4.5, 2.7, and 2.9/100 patient-years, respectively. However, major bleeding includes ICH and extracranial bleeding, particularly gastrointestinal bleeding. ICH is the most serious bleeding complication, since the likelihood of mortality or subsequent major disability is substantially higher than with bleeding at other sites [
         <a href="#rid46">
          46
         </a>
         ]. In this study and others, the annual risk of ICH in patients with AF who are not anticoagulated is estimated to be 0.2 percent/year; that risk approximately doubles with OAC with VKA [
         <a href="#rid34">
          34,37
         </a>
         ]. Randomized trials have shown that the risk of ICH with DOAC (both direct thrombin and factor Xa inhibitors) is approximately half of that with VKA  (
         <a class="graphic graphic_table graphicRef131871" href="/z/d/graphic/131871.html" rel="external">
          table 4
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/1031.html" rel="external">
          "Atrial fibrillation in adults: Use of oral anticoagulants", section on 'Choice of anticoagulant'
         </a>
         .)
        </p>
        <p>
         Given differences in morbidity associated with different types of bleeding, we think most patients would weigh the reduction in risk of ischemic stroke primarily against the increase in risk of ICH, with less weight given to the risk of gastrointestinal bleed or other less serious bleeding. While the incremental absolute risk of ICH with VKA (approximately 0.2 percent/year) is not trivial, it is substantially less than the expected absolute reduction in risk of ischemic stroke from OAC for most patients with AF and two or more nonsex CHA
         <sub>
          2
         </sub>
         DS
         <sub>
          2
         </sub>
         -VASc risk factors.
        </p>
        <p>
         One problem with the bleeding risk scores is that they were developed from studies that included bleeds of differing severity. While any bleed can lead to death or severe disability, most do not; the major exception is ICH. The morbidity associated with ICH is similar to that for ischemic stroke, while the morbidity associated with gastrointestinal bleeding is generally not as severe. (See
         <a class="medical medical_review" href="/z/d/html/119889.html" rel="external">
          "Risks and prevention of bleeding with oral anticoagulants", section on 'Intracranial'
         </a>
         .)
        </p>
        <p>
         For patients in the following clinical settings, the bleeding risk is significantly higher:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Thrombocytopenia or known coagulation defect associated with bleeding
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Active bleeding or recent surgery with a concern for ongoing bleeding
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prior severe bleeding (including ICH) while on an oral anticoagulant
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Aortic dissection
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Malignant hypertension
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Combined use of anticoagulant and antiplatelet (including regular use of nonsteroidal antiinflammatory) agents
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1047253330">
         <span class="h1">
          SPECIFIC PATIENT GROUPS
         </span>
        </p>
        <p class="headingAnchor" id="H3966449973">
         <span class="h2">
          Patients with valvular heart disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with valvular heart disease (excluding those with rheumatic mitral stenosis that is severe or clinically significant [mitral valve area ≤1.5 cm
         <sup>
          2
         </sup>
         ], a bioprosthetic valve [surgical or transcatheter] within the first three to six months after implantation, or a mechanical heart valve), the above general approach to deciding on oral anticoagulation (OAC) applies, although the evidence in patients with severe native valve disease is more limited than for the general population of patients with AF [
         <a href="#rid47">
          47
         </a>
         ]. (See
         <a class="local">
          'Approach to deciding whether to anticoagulate'
         </a>
         above.)
        </p>
        <p>
         Approaches to antithrombotic therapy (including anticoagulation) in patients with AF with specific valve conditions are discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rheumatic mitral stenosis that is severe or clinically significant (mitral valve area ≤1.5
         <sup>
         </sup>
         cm
         <sup>
          2
         </sup>
         ). (See
         <a class="medical medical_review" href="/z/d/html/8139.html" rel="external">
          "Rheumatic mitral stenosis: Overview of management", section on 'Prevention of thromboembolism'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mechanical heart valve. (See
         <a class="medical medical_review" href="/z/d/html/8171.html" rel="external">
          "Antithrombotic therapy for mechanical heart valves"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Surgically implanted bioprosthetic valve. (See
         <a class="medical medical_review" href="/z/d/html/8171.html" rel="external">
          "Antithrombotic therapy for mechanical heart valves"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Transcatheter bioprosthetic valve. (See
         <a class="medical medical_review" href="/z/d/html/131939.html" rel="external">
          "Transcatheter aortic valve implantation: Antithrombotic therapy", section on 'General approach'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2676296936">
         <span class="h2">
          AF type and management
         </span>
        </p>
        <p class="headingAnchor" id="H269515270">
         <span class="h3">
          Paroxysmal AF
         </span>
         <span class="headingEndMark">
          —
         </span>
         Our approach to deciding whether to anticoagulate is generally similar for patients with paroxysmal AF (PAF; with or without symptoms) as for persistent, or permanent, AF, as described above (see
         <a class="local">
          'Decision-making based upon risk assessment'
         </a>
         above). However, the burden of AF (duration and frequency of episodes) is a factor for decision-making for selected patients in whom the balance of benefit versus risk of anticoagulation is uncertain, recognizing that it may not be possible to accurately estimate AF burden except in patients with cardiac implantable electronic devices that can measure AF burden. We consider the burden of AF in decision-making for patients aged &lt;65 years and who have one nonsex CHA
         <sub>
          2
         </sub>
         DS
         <sub>
          2
         </sub>
         -VASc risk factor. On the other hand, patients with AF with past history of embolic stroke are at high risk for a recurrent thromboembolic event, so the burden of AF would generally not impact the decision to anticoagulate. (See
         <a class="local">
          'Decision-making based upon risk assessment'
         </a>
         above.)
        </p>
        <p>
         As discussed separately, the risk of thromboembolism in patients with PAF appears to be lower than in patients with persistent AF, and thromboembolic risk is higher in those with greater AF burden (percentage of time in AF). (See
         <a class="medical medical_review" href="/z/d/html/956.html" rel="external">
          "Paroxysmal atrial fibrillation", section on 'Risk of embolization'
         </a>
         .)
        </p>
        <p>
         There are no definitive data to establish a threshold duration of AF episodes for the initiation of anticoagulant therapy. Some of our experts recommend a single threshold for duration of AF of 30 seconds, and others use a threshold as long as 24 hours [
         <a href="#rid48">
          48
         </a>
         ]. Those experts who do not routinely anticoagulate patients with shorter-duration AF believe that the benefit is small and potentially outweighed by the bleeding risk. However, the AF burden is likely to vary over time, so a patient with 30 seconds of AF in one monitoring period may well have 30 hours of AF in the next monitoring period. While a large proportion of patients with short episodes of AF will go on to experience longer episodes, it is also true that the reverse occurs in a sizable percentage of patients experiencing long episodes of AF [
         <a href="#rid49">
          49
         </a>
         ]. Also, the extent to which thromboembolic risk may continue during periods of sinus rhythm is uncertain. (See
         <a class="medical medical_review" href="/z/d/html/956.html" rel="external">
          "Paroxysmal atrial fibrillation", section on 'Risk of embolization'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3042376200">
         <span class="h3">
          Device-detected AF
         </span>
         <span class="headingEndMark">
          —
         </span>
         Similar considerations apply to patients with device-detected (subclinical) AF as to patients with PAF, with the understanding that many patients with subclinical AF have very low AF burden.
        </p>
        <p>
         Device-detected AF (also known as subclinical AF or atrial high-rate episodes [AHRE]) is commonly identified in patients with a pacemaker, implantable cardioverter-defibrillator, or implanted cardiac monitor. The effects of anticoagulation for device-detected AF were assessed by a meta-analysis of two randomized controlled trials [
         <a href="#rid50">
          50
         </a>
         ]: a trial enrolling 2536 individuals (mean age 77.5 years; median CHA
         <sub>
          2
         </sub>
         DS
         <sub>
          2
         </sub>
         -VASc score 4; prior stroke, systemic embolism, or transient ischemic attack [TIA] 10 percent) with AHREs (median duration 2.8 hours; interquartile range [IQR] 0.8-9.2 hours) that compared
         <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">
          edoxaban
         </a>
         with placebo or
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         100 mg [
         <a href="#rid51">
          51
         </a>
         ] and a trial enrolling 4012 individuals (mean age 76.8 years; mean CHA
         <sub>
          2
         </sub>
         DS
         <sub>
          2
         </sub>
         -VASc score 3.9; prior stroke, systemic embolism, or TIA 9 percent) with subclinical AF (median duration 1.5 hours; IQR 0.2-5 hours) that compared
         <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">
          apixaban
         </a>
         with aspirin 81 mg [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p>
         The stroke rates were low in both arms of both trials [
         <a href="#rid50">
          50
         </a>
         ]. In the trial comparing
         <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">
          edoxaban
         </a>
         with placebo/
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         , ischemic stroke rates were 0.9 and 1.1 percent per patient-year [
         <a href="#rid51">
          51
         </a>
         ]. In the trial comparing
         <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">
          apixaban
         </a>
         with aspirin, ischemic stroke rates were 0.64 and 1.02 percent per patient-year [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p>
         Meta-analysis found that oral anticoagulation reduced ischemic stroke (relative risk [RR] 0.68, 95% CI 0.50-0.92) but did not reduce all-cause mortality (RR 1.08, 95% CI 0.96-1.21). Oral anticoagulation increased major bleeding (RR 1.62, 95% CI 1.05-2.5) [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2772192703">
         <span class="h3">
          Rhythm versus rate control
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with AF, the process of deciding whether to anticoagulate is generally the same regardless of the choice between rhythm control or rate control strategies. As discussed separately, the risk of thromboembolism is not reduced by clinical maintenance of sinus rhythm. (See
         <a class="medical medical_review" href="/z/d/html/1045.html" rel="external">
          "Management of atrial fibrillation: Rhythm control versus rate control", section on 'Thromboembolic risk'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1932859699">
         <span class="h3">
          AF after surgery
         </span>
         <span class="headingEndMark">
          —
         </span>
         Approaches to OAC in patients with AF after cardiac surgery and after noncardiac surgery are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1011.html" rel="external">
          "Atrial fibrillation and flutter after cardiac surgery", section on 'Our approach to postoperative anticoagulation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/113847.html" rel="external">
          "Atrial fibrillation in patients undergoing noncardiac surgery", section on 'Anticoagulation after surgery'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H271452366">
         <span class="h2">
          Older adults
         </span>
         <span class="headingEndMark">
          —
         </span>
         For older adults, we follow the general approach described above, including careful assessment the relative benefits and risks of OAC (see
         <a class="local">
          'Decision-making based upon risk assessment'
         </a>
         above). The approach to chronic kidney disease is discussed below. (See
         <a class="local">
          'Chronic kidney disease'
         </a>
         below.)
        </p>
        <p>
         In patients with documented frequent falls but without prior trauma (eg, fracture, subdural), we weight the risks and benefits of OAC versus left atrial appendage occlusion. In this clinical setting, we often recommend OAC and work to reduce the risk of falls. The risk of falls leading to subdural hematomas is increased in older adult patients taking oral anticoagulants independent of the agent chosen. (See
         <a class="medical medical_review" href="/z/d/html/119889.html" rel="external">
          "Risks and prevention of bleeding with oral anticoagulants", section on 'Age, race, and sex'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/928.html" rel="external">
          "Atrial fibrillation: Left atrial appendage occlusion"
         </a>
         .)
        </p>
        <p>
         A Taiwanese database study compared 15,756 older (≥90 years of age) adults with AF (11,064 receiving no antithrombotic therapy, 4075 receiving antiplatelet therapy, and 617 on
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         ) with 14,658 older adult patients without AF and without antithrombotic therapy [
         <a href="#rid53">
          53
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with AF had a greater risk of ischemic stroke (5.75 versus 3.00 percent/year; hazard ratio [HR] 1.93, 95% CI 1.74-2.14) and a similar risk of intracranial hemorrhage (ICH; 0.97 versus 0.54 percent/year; HR 0.85, 95% CI 0.66-1.09) compared with those without AF.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among patients with AF,
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         use was associated with a lower stroke risk (3.83 versus 5.75 percent/year; HR 0.69, 95% CI 0.49-0.96) compared with no antithrombotic therapy. There was a nominal but nonsignificant increase in risk of ICH (HR 1.26, 95% CI 0.70-2.25).
        </p>
        <p>
        </p>
        <p>
         In a second, later cohort of patients ≥90 years of age with AF, 768 patients treated with
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         were compared with 978 patients treated with a direct oral anticoagulant (DOAC) [
         <a href="#rid53">
          53
         </a>
         ]. DOACs were associated with a lower risk of ICH compared with warfarin (0.42 versus 1.63 percent/year; HR 0.32, 95% CI 0.10-0.97) and similar rate of ischemic stroke (4.07 versus 4.59 percent/year; HR 1.16; 95% CI 0.61–2.22). (See
         <a class="medical medical_review" href="/z/d/html/1031.html" rel="external">
          "Atrial fibrillation in adults: Use of oral anticoagulants", section on 'Older adults'
         </a>
         .)
        </p>
        <p>
         Potential use of reduced-dose DOAC (
         <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">
          edoxaban
         </a>
         ) in selected older adults with AF with low body weight is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1031.html" rel="external">
          "Atrial fibrillation in adults: Use of oral anticoagulants", section on 'DOACs'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4063726649">
         <span class="h2">
          Chronic kidney disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         For most patients with AF and chronic kidney disease (CKD), we follow the general approach to selection of candidates for OAC described above (see
         <a class="local">
          'Approach to deciding whether to anticoagulate'
         </a>
         above). However, some of our authors consider anticoagulation for the very uncommon CKD patient with a CHA
         <sub>
          2
         </sub>
         DS
         <sub>
          2
         </sub>
         -VASc score of 0 in males or 1 in females.
        </p>
        <p>
         For patients with CKD and AF, the following is our approach for deciding whether to anticoagulate  (
         <a class="graphic graphic_figure graphicRef59716" href="/z/d/graphic/59716.html" rel="external">
          figure 2
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Stages 2, 3, and 4 and 5 (not on dialysis)
         </strong>
         – For patients with estimated glomerular filtration rate (eGFR) of 15 to 89 mL/min/1.73 m
         <sup>
          2
         </sup>
         , our approach is similar to the general approach described above (see
         <a class="local">
          'Decision-making based upon risk assessment'
         </a>
         above), although there are very limited data for patients with end-stage kidney disease. Individualized risk assessment is performed to carefully weigh the benefits and risks of anticoagulation, with special attention to the bleeding risk associated with CKD. (See
         <a class="medical medical_review" href="/z/d/html/7172.html" rel="external">
          "Overview of the management of chronic kidney disease in adults", section on 'Uremic bleeding'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Stage 5 on dialysis
         </strong>
         – Among patients with end-stage kidney disease on dialysis, we anticoagulate some higher-risk individuals (based on the CHA
         <sub>
          2
         </sub>
         DS
         <sub>
          2-
         </sub>
         VASc score) after shared decision-making and discussion of risks and benefits between the clinician and the patient.
        </p>
        <p>
        </p>
        <p>
         However, it is reasonable to not anticoagulate the following groups of individuals with AF and eGFR &lt;30 mL/min (stages 4 and 5) given our uncertainty of the benefit-to-risk ratio for antithrombotic therapy in these patients:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with high frailty
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with prior life-threatening bleeding or recurrent bleeding
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with poorly controlled hypertension
        </p>
        <p>
        </p>
        <p>
         AF is common in patients with CKD [
         <a href="#rid54">
          54-59
         </a>
         ], with prevalence between 8 and 35 percent in patients on hemodialysis and approximately 7 percent in patients undergoing peritoneal dialysis [
         <a href="#rid60">
          60-62
         </a>
         ]. This rate is significantly higher than in the general population [
         <a href="#rid63">
          63-66
         </a>
         ]. Rates are even higher in studies which used prolonged/continuous monitoring for identifying AF  (
         <a class="graphic graphic_figure graphicRef55373" href="/z/d/graphic/55373.html" rel="external">
          figure 3
         </a>
         ) [
         <a href="#rid54">
          54,55,67
         </a>
         ]. CKD significantly increases thromboembolic risk above baseline and is also associated with increased risk of bleeding [
         <a href="#rid68">
          68-71
         </a>
         ]. Studies assessing the independent predictive value of presence of CKD for thromboembolic risk beyond the CHA
         <sub>
          2
         </sub>
         DS
         <sub>
          2
         </sub>
         -VASc score have yielded mixed results [
         <a href="#rid68">
          68,72,73
         </a>
         ]. The thromboembolic risk associated with CKD may be due to alterations in the normal hemostatic mechanisms. The increased bleeding risk, particularly from the gastrointestinal tract, is due to pathophysiologic mechanisms including impairment of normal platelet function secondary to factors such as uremic toxins, abnormal platelet arachidonic acid metabolism, altered von Willebrand factor, and reduction in intracellular adenosine diphosphate and serotonin, as well as an increase in the frequency of the need for invasive procedures [
         <a href="#rid63">
          63
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1947.html" rel="external">
          "Uremic platelet dysfunction"
         </a>
         .)
        </p>
        <p>
         The evidence to support OAC (vitamin K antagonist [VKA] or DOAC) is less robust in individuals with creatinine clearance &lt;30 mL/min, as many such patients were excluded from the important randomized trials [
         <a href="#rid74">
          74
         </a>
         ]. However, we believe that the benefit outweighs the risk in most cases.
        </p>
        <p>
         The efficacy and safety of
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         in patients with AF and CKD have been evaluated in observational studies which have come to differing conclusions [
         <a href="#rid69">
          69,75-80
         </a>
         ]. A 2020 meta-analysis of 15 studies (with a total of 47,480 patients with AF and end-stage renal disease) found no difference in the risk of ischemic stroke (HR 0.96, 95% CI 0.82-1.13), a higher risk of hemorrhage stroke (HR 1.46, 95% CI 1.05-2.04), and no significant difference in mortality (HR 0.95, 95% CI 0.83-1.09) or major bleeding (HR 1.20, 95% CI 0.99-1.47) in comparing warfarin users with those not taking warfarin [
         <a href="#rid81">
          81
         </a>
         ]. Many of the observational cohorts did not evaluate the quality of the OAC with warfarin, such as the time in the therapeutic range (TTR). This may be relevant since evidence suggests that higher TTR is associated with better outcomes. (See
         <a class="medical medical_review" href="/z/d/html/1334.html" rel="external">
          "Warfarin and other VKAs: Dosing and adverse effects", section on 'Monitoring (PT/INR)'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3047630980">
         <span class="h2">
          Hyperthyroidism
         </span>
         <span class="headingEndMark">
          —
         </span>
         The role of anticoagulant therapy is less well defined in patients in whom the underlying disease associated with AF can be corrected, as in hyperthyroidism. (See
         <a class="medical medical_review" href="/z/d/html/1004.html" rel="external">
          "Epidemiology, risk factors, and prevention of atrial fibrillation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7853.html" rel="external">
          "Cardiovascular effects of hyperthyroidism", section on 'Atrial fibrillation'
         </a>
         .)
        </p>
        <p>
         For patients with AF attributable to hyperthyroidism, we follow the general approach described above for identifying candidates for OAC. (See
         <a class="local">
          'Approach to deciding whether to anticoagulate'
         </a>
         above.)
        </p>
        <p>
         After successful treatment of the disorder, and after documentation that AF has not been present for at least three months, most of our experts suggest discontinuing anticoagulant treatment with periodic reassessment of the patient for recurrence of AF. We consider the absence of symptoms or signs of AF and two-week continuous monitoring showing no AF as adequate documentation. Some experts prefer additional documentation. However, some of our experts make a decision about continuing anticoagulant therapy based on the CHA
         <sub>
          2
         </sub>
         DS
         <sub>
          2
         </sub>
         -VASc score independent of monitored rhythm in these patients.
        </p>
        <p class="headingAnchor" id="H2470540196">
         <span class="h2">
          Hypertrophic cardiomyopathy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The role of OAC in patients with hypertrophic cardiomyopathy and AF is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4926.html" rel="external">
          "Hypertrophic cardiomyopathy in adults: Supraventricular tachycardias including atrial fibrillation", section on 'Long-term management'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H891703989">
         <span class="h2">
          Patients with cancer on chemotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several chemotherapy drugs have been associated with AF and atrial flutter. Depending on severity, dose reduction or discontinuation of the offending chemotherapy agent may be indicated. (See
         <a class="medical medical_review" href="/z/d/html/2812.html" rel="external">
          "Cardiotoxicity of cancer chemotherapy agents other than anthracyclines, HER2-targeted agents, and fluoropyrimidines"
         </a>
         .)
        </p>
        <p>
         For most patients with AF and cancer who are on chemotherapy, we follow the general approach to selection of candidates for OACs described above. (See
         <a class="local">
          'Approach to deciding whether to anticoagulate'
         </a>
         above.)
        </p>
        <p>
         For patients who have AF in the setting of chemotherapy-related thrombocytopenia, OACs may require a dose reduction in order to prevent bleeding. (See
         <a class="medical medical_review" href="/z/d/html/117208.html" rel="external">
          "Anticoagulation in individuals with thrombocytopenia", section on 'Atrial fibrillation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1217851751">
         <span class="h1">
          ALTERNATIVES TO ANTICOAGULATION
         </span>
        </p>
        <p class="headingAnchor" id="H1399022344">
         <span class="h2">
          Left atrial appendage occlusion
         </span>
         <span class="headingEndMark">
          —
         </span>
         As discussed separately, left atrial appendage occlusion is the primary alternative for patients with AF (excluding those with severe or clinically significant rheumatic stenosis, a bioprosthetic valve [surgical or bioprosthetic] within the first three to six months after implantation, or a mechanical valve) who have an indication for anticoagulation but have a contraindication for long-term anticoagulation. (See
         <a class="local">
          'Decision-making based upon risk assessment'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/928.html" rel="external">
          "Atrial fibrillation: Left atrial appendage occlusion"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2529360758">
         <span class="h2">
          Pharmacologic agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with AF, no other antithrombotic regimen is an effective and safe alternative to standard therapeutic oral anticoagulation (OAC). In this setting, other antithrombotic regimens are less effective in lowering thromboembolic risk than standard therapeutic OAC and some antithrombotic regimens entail a bleeding risk similar to or greater than standard therapeutic OAC:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Aspirin
         </strong>
         <strong>
          plus
         </strong>
         <strong>
          clopidogrel
         </strong>
         – Dual antiplatelet therapy is preferred to
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         alone in the occasional high-risk patient with AF who
         <strong>
          cannot
         </strong>
         be treated with any OAC for a reason other than risk of bleeding. Given the availability of the direct oral anticoagulant (DOAC) agents as alternatives to vitamin K antagonists (VKAs), this situation should be extremely uncommon. One possible example is a patient with contraindications to DOAC agents who cannot receive effective international normalized ratio (INR) monitoring for VKA. Of note, dual antiplatelet therapy and OAC have similar bleeding risks. Thus, a patient who would not be a candidate for OAC because of bleeding risk is also not a candidate for dual antiplatelet therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In patients with AF, dual antiplatelet therapy (with
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         plus
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         ) reduces the risk of thromboembolism compared with aspirin monotherapy but offers less protection against thromboembolism than OAC (with VKA or DOAC).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The safety and efficacy of dual antiplatelet therapy in patients with AF were investigated in the ACTIVE W and ACTIVE A trials. All patients in the two trials had AF and one or more risk factors for stroke. The primary endpoint in both trials was a composite outcome (the first occurrence of stroke, systemic [non-central nervous system] embolization, myocardial infarction, or vascular death). The ACTIVE W trial included 6706 patients who were randomly assigned to combined therapy with
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         (75 mg/day) and
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         (75 to 100 mg/day) or to OAC with a VKA (target INR 2.0 to 3.0) [
         <a href="#rid82">
          82
         </a>
         ]. The trial was stopped at an interim analysis after a median follow-up of 1.3 years because VKA lowered the annual rate of the primary endpoint compared with combined antiplatelet therapy (3.9 versus 5.6 percent; relative risk [RR] 0.69, 95% CI 0.57-0.85).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The ACTIVE A trial included 7554 patients with AF who were not candidates for
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         OAC and were randomly assigned to combined therapy with
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         (75 mg/day) and
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         (75 to 100 mg/day) or to aspirin alone at the same dose [
         <a href="#rid83">
          83
         </a>
         ]. After a median follow-up period of 3.6 years, patients treated with clopidogrel plus aspirin had a significantly lower annual rate of the primary combined endpoint (6.8 versus 7.8 percent; RR 0.89, 95% CI 0.81-0.98), which was primarily driven by a reduction in stroke (2.4 versus 3.3 percent; RR 0.72, 95% CI 0.62-0.83). On the other hand, dual antiplatelet therapy resulted in a higher rate of major bleeding (2.0 versus 1.3 percent/year; RR 1.57, 95% CI 1.29-1.92).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Aspirin
         </strong>
         <strong>
          monotherapy
         </strong>
         –
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          Aspirin
         </a>
         (or other antiplatelet agent) is not an effective therapy for preventing thromboembolic events in patients with AF. In patients with AF, some but not all meta-analyses of clinical trials comparing aspirin with placebo have found that aspirin reduced the risk of stroke and systemic embolism  (
         <a class="graphic graphic_table graphicRef66736" href="/z/d/graphic/66736.html" rel="external">
          table 6
         </a>
         ) [
         <a href="#rid14">
          14,38,84
         </a>
         ]. In contrast, clinical trials have demonstrated that OAC (with VKA or DOAC) lowers the risk of thromboembolism compared with aspirin  (
         <a class="graphic graphic_table graphicRef66736" href="/z/d/graphic/66736.html" rel="external">
          table 6
         </a>
         ) [
         <a href="#rid9">
          9,14-17,85-87
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Aspirin
         </strong>
         <strong>
          plus low-dose
         </strong>
         <strong>
          warfarin
         </strong>
         – In contrast to therapeutic adjusted-dose
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         (target INR 2.0 to 3.0), low-dose warfarin (1.25 mg/day or target INR between 1.2 and 1.5) in combination with
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         (300 to 325 mg/day) should
         <strong>
          not
         </strong>
         be used to reduce stroke risk in patients with nonvalvular AF [
         <a href="#rid17">
          17,88,89
         </a>
         ]. In the SPAF-III trial of 1044 patients with AF who were at high risk for embolism, low-dose warfarin plus aspirin had a much higher rate of ischemic stroke and systemic embolism than therapeutic adjusted-dose warfarin  (
         <a class="graphic graphic_figure graphicRef72790 graphicRef62833" href="/z/d/graphic/72790.html" rel="external">
          figure 4A-B
         </a>
         ) [
         <a href="#rid88">
          88
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Aspirin
         </strong>
         <strong>
          plus full-dose
         </strong>
         <strong>
          warfarin
         </strong>
         – Limited available data suggest that there is no benefit from adding
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         to therapeutic OAC in patients with AF. In a post-hoc analysis of the SPORTIF trials in patients with AF, among patients taking aspirin plus
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         (or aspirin plus the factor Xa inhibitor ximelagatran) experienced similar rates of stroke and systemic embolism as those taking warfarin alone (or ximelagatran alone) [
         <a href="#rid90">
          90
         </a>
         ]. The risk of major bleeding was higher with aspirin plus warfarin compared with warfarin alone (3.9 versus 2.3 percent/year).
        </p>
        <p>
        </p>
        <p>
         The management of antithrombotic therapy for patients with AF treated with OAC who have a concurrent indication for antiplatelet therapy is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1031.html" rel="external">
          "Atrial fibrillation in adults: Use of oral anticoagulants", section on 'Concomitant antiplatelet therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3932286547">
         <span class="h1">
          RECOMMENDATIONS OF OTHERS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Recommendations for choosing which patients with atrial fibrillation should be anticoagulated are available from the American Heart Association/American College of Cardiology/Heart Rhythm Society, the European Society of Cardiology, and the American College of Chest Physicians [
         <a href="#rid38">
          38,91-93
         </a>
         ]. In general, we agree with relevant recommendations made in these guidelines.
        </p>
        <p class="headingAnchor" id="H236370981">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/112091.html" rel="external">
          "Society guideline links: Atrial fibrillation"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/112260.html" rel="external">
          "Society guideline links: Arrhythmias in adults"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/114614.html" rel="external">
          "Society guideline links: Anticoagulation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H269597360">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15327.html" rel="external">
          "Patient education: Atrial fibrillation (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/16237.html" rel="external">
          "Patient education: Medicines for atrial fibrillation (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/16265.html" rel="external">
          "Patient education: Choosing an oral medicine for blood clots (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/86638.html" rel="external">
          "Patient education: Taking oral medicines for blood clots (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/3431.html" rel="external">
          "Patient education: Atrial fibrillation (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/689.html" rel="external">
          "Patient education: Warfarin (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2628656711">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Role of oral anticoagulation (OAC) in atrial fibrillation (AF)
         </strong>
         – In patients with AF, OAC reduces the risk of thromboembolism by approximately two-thirds across clinical risk factor profiles but also entails an increased risk of major bleeding.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Deciding whether to anticoagulate
         </strong>
         – For each patient, their estimated absolute risk reduction for thromboembolic events is weighed against their estimated increase in absolute risk of intracranial hemorrhage and other life-threatening or severely debilitating bleeding complications. (See
         <a class="local">
          'Approach to deciding whether to anticoagulate'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          CHA
         </strong>
         <strong>
          <sub>
           2
          </sub>
         </strong>
         <strong>
          DS
         </strong>
         <strong>
          <sub>
           2
          </sub>
         </strong>
         <strong>
          -VASc risk score
         </strong>
         – Our approach to deciding whether to prescribe anticoagulant therapy for patients with AF (excluding those with rheumatic mitral stenosis that is severe or clinically significant [mitral valve area ≤1.5 cm
         <sup>
          2
         </sup>
         ], a bioprosthetic valve [surgical or transcatheter] within the first three to six months after implantation, or a mechanical heart valve) is as follows (see
         <a class="local">
          'Approach to deciding whether to anticoagulate'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For a CHA
         <sub>
          2
         </sub>
         DS
         <sub>
          2
         </sub>
         -VASc score ≥2 in males or ≥3 in females (
         <a class="calc calc_professional" href="/z/d/html/99815.html" rel="external">
          calculator 1
         </a>
         )  (
         <a class="graphic graphic_table graphicRef94752" href="/z/d/graphic/94752.html" rel="external">
          table 1
         </a>
         ), we recommend chronic OAC (
         <a class="grade" href="https:///uptodate/show/grade_1" rel="external">
          Grade 1A
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For a CHA
         <sub>
          2
         </sub>
         DS
         <sub>
          2
         </sub>
         -VASc score of 1 in males and 2 in females (
         <a class="calc calc_professional" href="/z/d/html/99815.html" rel="external">
          calculator 1
         </a>
         )  (
         <a class="graphic graphic_table graphicRef94752" href="/z/d/graphic/94752.html" rel="external">
          table 1
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For patients with CHA
         <sub>
          2
         </sub>
         DS
         <sub>
          2
         </sub>
         -VASc score of 1 in males and 2 in females based on age 65 to 74 years, we recommend chronic OAC (
         <a class="grade" href="https:///uptodate/show/grade_1" rel="external">
          Grade 1A
         </a>
         ). Age 65 to 74 years is a stronger risk factor than the other factors conferring one CHA
         <sub>
          2
         </sub>
         DS
         <sub>
          2
         </sub>
         -VASc score point.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For patients with other risk factors, the decision to anticoagulate is based upon the specific nonsex risk factor and the burden of AF. For patients with very low burden of AF (eg, AF that is well documented as limited to an isolated episode that may have been due to a reversible cause such as recent surgery, heavy alcohol ingestion, or sleep deprivation), it may be reasonable to forgo chronic OAC and institute close surveillance for recurrent AF, although it may not be possible to reliably estimate AF burden from surveying symptoms or infrequent monitoring. (See
         <a class="medical medical_review" href="/z/d/html/113847.html" rel="external">
          "Atrial fibrillation in patients undergoing noncardiac surgery", section on 'Anticoagulation after surgery'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1011.html" rel="external">
          "Atrial fibrillation and flutter after cardiac surgery", section on 'Anticoagulation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with a CHA
         <sub>
          2
         </sub>
         DS
         <sub>
          2
         </sub>
         -VASc of 0 in males or 1 in females (
         <a class="calc calc_professional" href="/z/d/html/99815.html" rel="external">
          calculator 1
         </a>
         )  (
         <a class="graphic graphic_table graphicRef94752" href="/z/d/graphic/94752.html" rel="external">
          table 1
         </a>
         ), we suggest
         <strong>
          against
         </strong>
         OAC (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Patient values and preferences may impact the decision. For example, a patient who is particularly stroke averse and is not at increased risk for bleeding (see
         <a class="local">
          'Bleeding risk'
         </a>
         above) may reasonably choose anticoagulation, particularly if the patient is a candidate for treatment with a direct oral anticoagulant (DOAC).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bleeding risk
         </strong>
         – For all potential candidates for OAC, bleeding risk and related possible contraindications to OAC should be reviewed  (
         <a class="graphic graphic_table graphicRef107527" href="/z/d/graphic/107527.html" rel="external">
          table 2
         </a>
         and
         <a class="graphic graphic_table graphicRef75259" href="/z/d/graphic/75259.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="local">
          'Bleeding risk'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The appropriate use of bleeding risk assessment is to draw attention to modifiable bleeding risk factors that can be mitigated to flag high-bleeding-risk patients for early review and follow-up. (See
         <a class="medical medical_review" href="/z/d/html/119889.html" rel="external">
          "Risks and prevention of bleeding with oral anticoagulants", section on 'Bleeding risk scores'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1324.html" rel="external">
          "Management of warfarin-associated bleeding or supratherapeutic INR", section on 'Mitigating bleeding risk'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Specific patient groups
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Paroxysmal AF
         </strong>
         – Our approach to deciding whether to anticoagulate is generally similar for patients with paroxysmal AF (PAF; with or without symptoms) as for persistent, or permanent, AF, as described above (see
         <a class="local">
          'Decision-making based upon risk assessment'
         </a>
         above). However, the burden of AF (duration and frequency of episodes) is a factor for decision-making for selected patients in whom the balance of benefit versus risk of anticoagulation is uncertain. (See
         <a class="local">
          'Paroxysmal AF'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Similar considerations apply to patients with device-detected (subclinical) AF, with the understanding that many patients with subclinical AF have very low AF burden. (See
         <a class="local">
          'Device-detected AF'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Concurrent conditions
         </strong>
         – Our approach to OAC for patients with AF who are older, have chronic kidney disease, hyperthyroidism, and hypertrophic cardiomyopathy can sometimes differ for patients who are younger or do not have these conditions. (See
         <a class="local">
          'Specific patient groups'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Contraindication to OAC
         </strong>
         – For patients with AF (excluding those with severe or clinically significant rheumatic stenosis, a surgical bioprosthetic valve within the first three to six months after implantation, or a mechanical valve) with an indication for OAC but who have a contraindication for long-term OAC, the primary alternative is left atrial appendage occlusion. For such patients, no other antithrombotic regimen is an effective and safe alternative to standard therapeutic OAC. (See
         <a class="local">
          'Alternatives to anticoagulation'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/928.html" rel="external">
          "Atrial fibrillation: Left atrial appendage occlusion"
         </a>
         .)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Lee CJ, Toft-Petersen AP, Ozenne B, et al. Assessing absolute stroke risk in patients with atrial fibrillation using a risk factor-based approach. Eur Heart J Cardiovasc Pharmacother 2021; 7:f3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borre ED, Goode A, Raitz G, et al. Predicting Thromboembolic and Bleeding Event Risk in Patients with Non-Valvular Atrial Fibrillation: A Systematic Review. Thromb Haemost 2018; 118:2171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lip GY, Lane DA. Bleeding risk assessment in atrial fibrillation: observations on the use and misuse of bleeding risk scores. J Thromb Haemost 2016; 14:1711.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lip GY, Lane DA. Assessing bleeding risk in atrial fibrillation with the HAS-BLED and ORBIT scores: clinical application requires focus on the reversible bleeding risk factors. Eur Heart J 2015; 36:3265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guo Y, Lane DA, Chen Y, et al. Regular Bleeding Risk Assessment Associated with Reduction in Bleeding Outcomes: The mAFA-II Randomized Trial. Am J Med 2020; 133:1195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fang MC, Go AS, Chang Y, et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol 2011; 58:395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators, Singer DE, Hughes RA, et al. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990; 323:1505.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991; 84:527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994; 343:687.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Petersen P, Boysen G, Godtfredsen J, et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989; 1:175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 1992; 327:1406.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Connolly SJ, Laupacis A, Gent M, et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991; 18:349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154:1449.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146:857.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Walraven C, Hart RG, Singer DE, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 2002; 288:2441.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cooper NJ, Sutton AJ, Lu G, Khunti K. Mixed comparison of stroke prevention treatments in individuals with nonrheumatic atrial fibrillation. Arch Intern Med 2006; 166:1269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McNamara RL, Tamariz LJ, Segal JB, Bass EB. Management of atrial fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography. Ann Intern Med 2003; 139:1018.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okumura K, Akao M, Yoshida T, et al. Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation. N Engl J Med 2020; 383:1735.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friberg L, Rosenqvist M, Lip GY. Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation 2012; 125:2298.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nielsen PB, Chao TF. The risks of risk scores for stroke risk assessment in atrial fibrillation. Thromb Haemost 2015; 113:1170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nielsen PB, Larsen TB, Skjøth F, et al. Stroke and thromboembolic event rates in atrial fibrillation according to different guideline treatment thresholds: A nationwide cohort study. Sci Rep 2016; 6:27410.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quinn GR, Severdija ON, Chang Y, Singer DE. Wide Variation in Reported Rates of Stroke Across Cohorts of Patients With Atrial Fibrillation. Circulation 2017; 135:208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quinn GR, Severdija ON, Chang Y, et al. Methodologic Differences Across Studies of Patients With Atrial Fibrillation Lead to Varying Estimates of Stroke Risk. J Am Heart Assoc 2018; 7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah SJ, Eckman MH, Aspberg S, et al. Effect of Variation in Published Stroke Rates on the Net Clinical Benefit of Anticoagulation for Atrial Fibrillation. Ann Intern Med 2018; 169:517.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friberg L, Skeppholm M, Terént A. Benefit of anticoagulation unlikely in patients with atrial fibrillation and a CHA2DS2-VASc score of 1. J Am Coll Cardiol 2015; 65:225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chao TF, Liu CJ, Wang KL, et al. Using the CHA2DS2-VASc score for refining stroke risk stratification in 'low-risk' Asian patients with atrial fibrillation. J Am Coll Cardiol 2014; 64:1658.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lip GY, Skjøth F, Rasmussen LH, Larsen TB. Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score. J Am Coll Cardiol 2015; 65:1385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bekwelem W, Connolly SJ, Halperin JL, et al. Extracranial Systemic Embolic Events in Patients With Nonvalvular Atrial Fibrillation: Incidence, Risk Factors, and Outcomes. Circulation 2015; 132:796.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnsen SP, Svendsen ML, Hansen ML, et al. Preadmission oral anticoagulant treatment and clinical outcome among patients hospitalized with acute stroke and atrial fibrillation: a nationwide study. Stroke 2014; 45:168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nielsen PB, Skjøth F, Overvad TF, et al. Female Sex Is a Risk Modifier Rather Than a Risk Factor for Stroke in Atrial Fibrillation: Should We Use a CHA2DS2-VA Score Rather Than CHA2DS2-VASc? Circulation 2018; 137:832.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singer DE, Chang Y, Fang MC, et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009; 151:297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olesen JB, Lip GY, Lindhardsen J, et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost 2011; 106:739.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Banerjee A, Lane DA, Torp-Pedersen C, Lip GY. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost 2012; 107:584.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Go AS, Hylek EM, Chang Y, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 2003; 290:2685.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hart RG, Pearce LA. Current status of stroke risk stratification in patients with atrial fibrillation. Stroke 2009; 40:2607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agarwal S, Hachamovitch R, Menon V. Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis. Arch Intern Med 2012; 172:623.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gallagher AM, van Staa TP, Murray-Thomas T, et al. Population-based cohort study of warfarin-treated patients with atrial fibrillation: incidence of cardiovascular and bleeding outcomes. BMJ Open 2014; 4:e003839.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lip GYH, Banerjee A, Boriani G, et al. Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report. Chest 2018; 154:1121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Providência R, Trigo J, Paiva L, Barra S. The role of echocardiography in thromboembolic risk assessment of patients with nonvalvular atrial fibrillation. J Am Soc Echocardiogr 2013; 26:801.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kezerle L, Tsadok MA, Akriv A, et al. Pre-Diabetes Increases Stroke Risk in Patients With Nonvalvular Atrial Fibrillation. J Am Coll Cardiol 2021; 77:875.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Proietti M, Romiti GF, Vitolo M, et al. Comparison of HAS-BLED and ORBIT bleeding risk scores in atrial fibrillation patients treated with non-vitamin K antagonist oral anticoagulants: a report from the ESC-EHRA EORP-AF General Long-Term Registry. Eur Heart J Qual Care Clin Outcomes 2022; 8:778.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wattanaruengchai P, Nathisuwan S, Karaketklang K, et al. Comparison of the HAS-BLED versus ORBIT scores in predicting major bleeding among Asians receiving direct-acting oral anticoagulants. Br J Clin Pharmacol 2022; 88:2203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poli D, Antonucci E, Grifoni E, et al. Bleeding risk during oral anticoagulation in atrial fibrillation patients older than 80 years. J Am Coll Cardiol 2009; 54:999.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol. 2006; 48:e149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hughes M, Lip GY, Guideline Development Group for the NICE national clinical guideline for management of atrial fibrillation in primary and secondary care. Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: a systematic review. QJM 2007; 100:599.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fang MC, Go AS, Chang Y, et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med 2007; 120:700.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2021; 143:e72.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Gelder IC, Healey JS, Crijns HJGM, et al. Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT. Eur Heart J 2017; 38:1339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diederichsen SZ, Haugan KJ, Brandes A, et al. Natural History of Subclinical Atrial Fibrillation Detected by Implanted Loop Recorders. J Am Coll Cardiol 2019; 74:2771.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McIntyre WF, Benz AP, Becher N, et al. Direct Oral Anticoagulants for Stroke Prevention in Patients with Device-Detected Atrial Fibrillation: A Study-Level Meta-Analysis of the NOAH-AFNET 6 and ARTESiA Trials. Circulation 2023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kirchhof P, Toennis T, Goette A, et al. Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes. N Engl J Med 2023; 389:1167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Healey JS, Lopes RD, Granger CB, et al. Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation. N Engl J Med 2024; 390:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chao TF, Liu CJ, Lin YJ, et al. Oral Anticoagulation in Very Elderly Patients With Atrial Fibrillation: A Nationwide Cohort Study. Circulation 2018; 138:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vázquez E, Sánchez-Perales C, Borrego F, et al. Influence of atrial fibrillation on the morbido-mortality of patients on hemodialysis. Am Heart J 2000; 140:886.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Genovesi S, Pogliani D, Faini A, et al. Prevalence of atrial fibrillation and associated factors in a population of long-term hemodialysis patients. Am J Kidney Dis 2005; 46:897.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vazquez E, Sanchez-Perales C, Garcia-Garcia F, et al. Atrial fibrillation in incident dialysis patients. Kidney Int 2009; 76:324.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wetmore JB, Mahnken JD, Rigler SK, et al. The prevalence of and factors associated with chronic atrial fibrillation in Medicare/Medicaid-eligible dialysis patients. Kidney Int 2012; 81:469.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285:2370.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pokorney SD, Black-Maier E, Hellkamp AS, et al. Oral Anticoagulation and Cardiovascular Outcomes in Patients With Atrial Fibrillation and End-Stage Renal Disease. J Am Coll Cardiol 2020; 75:1299.
          </a>
         </li>
         <li class="breakAll">
          US Renal Data System: USRDS 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, National Institutes of Health, National Institute of Diabetes, and Digestive and Kidney Diseases, 2005.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winkelmayer WC, Patrick AR, Liu J, et al. The increasing prevalence of atrial fibrillation among hemodialysis patients. J Am Soc Nephrol 2011; 22:349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang F, Chou D, Schweitzer P, Hanon S. Warfarin in haemodialysis patients with atrial fibrillation: what benefit? Europace 2010; 12:1666.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marinigh R, Lane DA, Lip GY. Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk. J Am Coll Cardiol 2011; 57:1339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Atar I, Konaş D, Açikel S, et al. Frequency of atrial fibrillation and factors related to its development in dialysis patients. Int J Cardiol 2006; 106:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abbott KC, Trespalacios FC, Taylor AJ, Agodoa LY. Atrial fibrillation in chronic dialysis patients in the United States: risk factors for hospitalization and mortality. BMC Nephrol 2003; 4:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005; 45:S1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bozbas H, Atar I, Yildirir A, et al. Prevalence and predictors of arrhythmia in end stage renal disease patients on hemodialysis. Ren Fail 2007; 29:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Go AS, Fang MC, Udaltsova N, et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 2009; 119:1363.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olesen JB, Lip GY, Kamper AL, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 2012; 367:625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Limdi NA, Beasley TM, Baird MF, et al. Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol 2009; 20:912.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakayama M, Metoki H, Terawaki H, et al. Kidney dysfunction as a risk factor for first symptomatic stroke events in a general Japanese population--the Ohasama study. Nephrol Dial Transplant 2007; 22:1910.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roldán V, Marín F, Manzano-Fernandez S, et al. Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation? Thromb Haemost 2013; 109:956.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kornej J, Hindricks G, Kosiuk J, et al. Renal dysfunction, stroke risk scores (CHADS2, CHA2DS2-VASc, and R2CHADS2), and the risk of thromboembolic events after catheter ablation of atrial fibrillation: the Leipzig Heart Center AF Ablation Registry. Circ Arrhythm Electrophysiol 2013; 6:868.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ha JT, Neuen BL, Cheng LP, et al. Benefits and Harms of Oral Anticoagulant Therapy in Chronic Kidney Disease: A Systematic Review and Meta-analysis. Ann Intern Med 2019; 171:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan KE, Lazarus JM, Thadhani R, Hakim RM. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol 2009; 20:2223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wizemann V, Tong L, Satayathum S, et al. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int 2010; 77:1098.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winkelmayer WC, Liu J, Setoguchi S, Choudhry NK. Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation. Clin J Am Soc Nephrol 2011; 6:2662.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah M, Avgil Tsadok M, Jackevicius CA, et al. Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis. Circulation 2014; 129:1196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carrero JJ, Evans M, Szummer K, et al. Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation. JAMA 2014; 311:919.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonde AN, Lip GY, Kamper AL, et al. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. J Am Coll Cardiol 2014; 64:2471.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Randhawa MS, Vishwanath R, Rai MP, et al. Association Between Use of Warfarin for Atrial Fibrillation and Outcomes Among Patients With End-Stage Renal Disease: A Systematic Review and Meta-analysis. JAMA Netw Open 2020; 3:e202175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367:1903.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ACTIVE Investigators, Connolly SJ, Pogue J, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009; 360:2066.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tereshchenko LG, Henrikson CA, Cigarroa J, Steinberg JS. Comparative Effectiveness of Interventions for Stroke Prevention in Atrial Fibrillation: A Network Meta-Analysis. J Am Heart Assoc 2016; 5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994; 120:897.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Själander S, Själander A, Svensson PJ, Friberg L. Atrial fibrillation patients do not benefit from acetylsalicylic acid. Europace 2014; 16:631.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364:806.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996; 348:633.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gulløv AL, Koefoed BG, Petersen P, et al. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med 1998; 158:1513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flaker GC, Gruber M, Connolly SJ, et al. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. Am Heart J 2006; 152:967.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014; 130:e199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation 2019; 140:e125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021; 42:373.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 128998 Version 12.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32531029" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Assessing absolute stroke risk in patients with atrial fibrillation using a risk factor-based approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30376678" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Predicting Thromboembolic and Bleeding Event Risk in Patients with Non-Valvular Atrial Fibrillation: A Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27296528" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Bleeding risk assessment in atrial fibrillation: observations on the use and misuse of bleeding risk scores.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26351397" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Assessing bleeding risk in atrial fibrillation with the HAS-BLED and ORBIT scores: clinical application requires focus on the reversible bleeding risk factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32289310" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Regular Bleeding Risk Assessment Associated with Reduction in Bleeding Outcomes: The mAFA-II Randomized Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21757117" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2233931" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1860198" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Stroke Prevention in Atrial Fibrillation Study. Final results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7907677" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2563096" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1406859" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1856403" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Canadian Atrial Fibrillation Anticoagulation (CAFA) Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8018000" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17577005" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12435257" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16801509" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Mixed comparison of stroke prevention treatments in individuals with nonrheumatic atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14678922" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Management of atrial fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32865374" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22514252" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25759209" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : The risks of risk scores for stroke risk assessment in atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27265586" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Stroke and thromboembolic event rates in atrial fibrillation according to different guideline treatment thresholds: A nationwide cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27799272" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Wide Variation in Reported Rates of Stroke Across Cohorts of Patients With Atrial Fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29886417" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Methodologic Differences Across Studies of Patients With Atrial Fibrillation Lead to Varying Estimates of Stroke Risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30264130" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Effect of Variation in Published Stroke Rates on the Net Clinical Benefit of Anticoagulation for Atrial Fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25614418" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Benefit of anticoagulation unlikely in patients with atrial fibrillation and a CHA2DS2-VASc score of 1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25323252" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Using the CHA2DS2-VASc score for refining stroke risk stratification in 'low-risk' Asian patients with atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25770314" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26224811" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Extracranial Systemic Embolic Events in Patients With Nonvalvular Atrial Fibrillation: Incidence, Risk Factors, and Outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24281225" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Preadmission oral anticoagulant treatment and clinical outcome among patients hospitalized with acute stroke and atrial fibrillation: a nationwide study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29459469" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Female Sex Is a Risk Modifier Rather Than a Risk Factor for Stroke in Atrial Fibrillation: Should We Use a CHA2DS2-VA Score Rather Than CHA2DS2-VASc?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19721017" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : The net clinical benefit of warfarin anticoagulation in atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21789337" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22186961" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14645310" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19461020" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Current status of stroke risk stratification in patients with atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22450212" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24468720" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Population-based cohort study of warfarin-treated patients with atrial fibrillation: incidence of cardiovascular and bleeding outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30144419" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23791115" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : The role of echocardiography in thromboembolic risk assessment of patients with nonvalvular atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33602470" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Pre-Diabetes Increases Stroke Risk in Patients With Nonvalvular Atrial Fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34555148" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Comparison of HAS-BLED and ORBIT bleeding risk scores in atrial fibrillation patients treated with non-vitamin K antagonist oral anticoagulants: a report from the ESC-EHRA EORP-AF General Long-Term Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34783372" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Comparison of the HAS-BLED versus ORBIT scores in predicting major bleeding among Asians receiving direct-acting oral anticoagulants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19729116" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Bleeding risk during oral anticoagulation in atrial fibrillation patients older than 80 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17846060" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17679129" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Death and disability from warfarin-associated intracranial and extracranial hemorrhages.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33332150" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28329139" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31779791" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Natural History of Subclinical Atrial Fibrillation Detected by Implanted Loop Recorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37952187" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Direct Oral Anticoagulants for Stroke Prevention in Patients with Device-Detected Atrial Fibrillation: A Study-Level Meta-Analysis of the NOAH-AFNET 6 and ARTESiA Trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37622677" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37952132" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29490992" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Oral Anticoagulation in Very Elderly Patients With Atrial Fibrillation: A Nationwide Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11099992" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Influence of atrial fibrillation on the morbido-mortality of patients on hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16253730" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Prevalence of atrial fibrillation and associated factors in a population of long-term hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19494800" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Atrial fibrillation in incident dialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22189842" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : The prevalence of and factors associated with chronic atrial fibrillation in Medicare/Medicaid-eligible dialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11343485" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32192656" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Oral Anticoagulation and Cardiovascular Outcomes in Patients With Atrial Fibrillation and End-Stage Renal Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32192656" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Oral Anticoagulation and Cardiovascular Outcomes in Patients With Atrial Fibrillation and End-Stage Renal Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21233416" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : The increasing prevalence of atrial fibrillation among hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21045011" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Warfarin in haemodialysis patients with atrial fibrillation: what benefit?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21414530" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16321665" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Frequency of atrial fibrillation and factors related to its development in dialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12546711" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Atrial fibrillation in chronic dialysis patients in the United States: risk factors for hospitalization and mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15806502" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17497448" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Prevalence and predictors of arrhythmia in end stage renal disease patients on hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19255343" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22894575" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Stroke and bleeding in atrial fibrillation with chronic kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19225037" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Kidney function influences warfarin responsiveness and hemorrhagic complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17395659" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Kidney dysfunction as a risk factor for first symptomatic stroke events in a general Japanese population--the Ohasama study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23572113" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24047706" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Renal dysfunction, stroke risk scores (CHADS2, CHA2DS2-VASc, and R2CHADS2), and the risk of thromboembolic events after catheter ablation of atrial fibrillation: the Leipzig Heart Center AF Ablation Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31307056" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Benefits and Harms of Oral Anticoagulant Therapy in Chronic Kidney Disease: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19713308" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20054291" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21959598" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24452752" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24595776" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25500231" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32250434" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Association Between Use of Warfarin for Atrial Fibrillation and Outcomes Among Patients With End-Stage Renal Disease: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16765759" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19336502" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27207998" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Comparative Effectiveness of Interventions for Stroke Prevention in Atrial Fibrillation: A Network Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8172435" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Risk factors for intracranial hemorrhage in outpatients taking warfarin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24158253" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Atrial fibrillation patients do not benefit from acetylsalicylic acid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21309657" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Apixaban in patients with atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8782752" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9679792" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17070169" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24682347" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30686041" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32860505" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
